Lucid Capital analyst Elemer Piros initiated coverage of Passage Bio (PASG) with a Buy rating and $68 price target Passage Bio, which has developed a one-time gene therapy treatment, PBFT02, to correct certain genetic defects that lead to frontotemporal dementia is “at the forefront of treating dementia with one-time gene therapies,” the analyst tells investors.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PASG:
- PASG Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- 3 Best Biotech Stocks to Buy Now, 11/12/2025, According to Top Analysts
- Passage Bio’s Growth Potential Highlighted by Clinical Progress and Regulatory Alignment
- Passage Bio Reports Q3 Financial Results and Updates
- Passage Bio reports Q3 EPS ($2.44), consensus ($2.97)